Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress
- None.
- None.
Insights
Celldex to present pivotal Phase 2 data showing sustained efficacy of barzolvolimab in chronic urticaria, potentially advancing their lead candidate toward commercialization.
Celldex's upcoming presentation of Phase 2 data for barzolvolimab in chronic spontaneous urticaria (CSU) represents a significant milestone in their clinical development program. The data to be presented includes 76-week efficacy and tolerability results as well as 52-week angioedema data, which suggests robust and extended follow-up that will help establish the drug's long-term profile.
Most notably, the late-breaking oral presentation titled "Sustained Disease Control Following Withdrawal of Barzolvolimab" indicates potentially positive durability data - a critical differentiator in the competitive CSU landscape currently dominated by biologics requiring frequent administration. This durability aspect could significantly enhance the commercial positioning of barzolvolimab if approved.
The second presentation specifically addressing angioedema (a painful swelling that often accompanies CSU) suggests the drug may provide comprehensive symptom relief. Approximately 40% of CSU patients experience angioedema, which represents a substantial unmet need in treatment.
The involvement of prominent dermatology experts like Dr. Martin Metz from Charité – Universitätsmedizin and Dr. Ana Maria Giménez-Arnau indicates strong academic interest in the program. Their participation lends scientific credibility to the findings and suggests the data may be practice-changing.
The company's decision to host a same-day webcast underscores management's confidence in the data and their commitment to promptly communicating results to investors and the scientific community. For Celldex, whose pipeline is heavily weighted toward barzolvolimab across multiple indications, positive Phase 2 CSU data could significantly de-risk their lead program and potentially accelerate the path toward pivotal trials.
Company to host webcast on Thursday, June 12 at 6:00 pm ET
HAMPTON, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that data from the Company’s Phase 2 study of barzolvolimab in chronic spontaneous urticaria will be presented at the EAACI Congress 2025 being held in Glasgow, Scotland. Abstracts will be available on the meeting website Thursday, June 12th at 6:01 pm ET/ Friday, June 13th at 12:01 am CEST. Celldex will host a webcast on Thursday, June 12th at 6:00 pm ET to discuss the data.
Phase 2 CSU 76 Week Efficacy and Tolerability Data
Company Webcast and Conference Call
Date & Time: Thursday, June 12th at 6:00 pm ET/11:00 pm BST
Presenters: Company representatives and Martin Metz, MD, Professor, Department of Dermatology and Allergy, Head of Translation Research and Deputy Head of Clinical Trials at Charité – Universitätsmedizin in Berlin and lead investigator for the Phase 2 CSU study
Webcast Access: Please visit the Events section on the Investor Relations page of Celldex's website to register for the webcast. Parties interested in participating via telephone may register here to receive the dial-in numbers and unique PIN to seamlessly access the call.
EAACI Presentation Session
Date & Time: Friday, June 13th at 9:12 am BST/4:12 am ET
Late Breaking Oral Presentation 100227: Sustained Disease Control Following Withdrawal of Barzolvolimab in Patients with Chronic Spontaneous Urticaria
Presenting Author: Ana Maria Giménez-Arnau, MD, PhD, Associate Professor of Dermatology
Autonomous University and Pompeu Fabra University
Phase 2 CSU 52 Week Angioedema Data
EAACI Session Date & Time: Saturday, June 14th at 3:48 pm BST/10:48 am ET
Oral Presentation 000588: Treatment with Barzolvolimab Leads to Sustained Improvement in Angioedema in Chronic Spontaneous Urticaria (CSU) patients: Results from 52 Weeks of Treatment
Presenting Author: Martin Metz, MD, Professor, Department of Dermatology and Allergy, Head of Translation Research and Deputy Head of Clinical Trials at Charité – Universitätsmedizin in Berlin and lead investigator for the Phase 2 CSU study
About Celldex
Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders. Visit www.celldex.com.
Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
scavanaugh@celldex.com
Patrick Till
Meru Advisors
(484) 788-8560
ptill@meruadvisors.com
FAQ
What data will Celldex (CLDX) present at EAACI 2025 for barzolvolimab?
When is Celldex's (CLDX) webcast to discuss barzolvolimab Phase 2 data?
Who are the key presenters for Celldex's (CLDX) barzolvolimab data at EAACI 2025?
What is the schedule for Celldex's (CLDX) presentations at EAACI 2025?
